About AE   About NHM   Contact Us   Terms of Use   Copyright Info   Privacy Policy   Advertising Policies   Site Map
Custom Search of AE Site
spacer spacer

HIV to the Rescue?

By Sean Henahan, Access Excellence

HIV gene therapyLa Jolla, CA (1/28/99)- Some of the most valuable medical treatments, like the vaccines for small pox and rabies, are based on weakened version of pathogenic organisms. Researchers from the Salk Institute now report that one of the deadliest pathogens known to man, HIV, may, with careful modification, prove to be an optimal vector for gene therapy.

Can HIV Redeem Itself as a Vector for Gene Therapy?

Hiroyuki Miyoshi and colleagues created a modified version of HIV (human immunodeficiency virus, the cause of AIDS) and then spliced in genes from human hematopoietic stem cells (HSCs). When they injected the cocktail into mice, they saw signs of HSC expression in the animals' bloodstream and bone marrow. The transferred cells survived and differentiated in the mice for at least five months.

Hematopoietic stem cells residing in bone marrow are the progenitors of all the different types of components of the bloodstream. Researchers have long sought a method to introduce healthy stem cells into the bloodstream of patients with inherited blood disorders such as sickle cell anemia, as well as certain cancers including leukemia. The hope is that the fresh stem cells would transfer genes to the faulty stem cells of the patients, allowing regeneration of healthy blood.

"This will open the door to many applications, including thalassemias, sickle-cell anemias, hemophilias and certain cancers. Stem cells are capable of becoming any type of cell in the blood, from immune system cells to oxygen-ferrying red blood cells," said Inder Verma, a professor at the Salk institute.

Verma was part of the team that developed the attenuated version of HIV used as the vector. Retroviruses (like HIV) enter their host's cells and copy their own genetic material into the cell's nucleus. Thus, the same thing that makes them so destructive as pathogens, also makes them potentially very good vectors, or delivery vehicles, for gene therapy.

Scientists have already had some success with retroviral vectors. While researchers have been able to deliver genes via this method to mouse hematopoetic stem cells, the Salk team is the first to report the delivery of stem cells from humans into mice.

"This is probably because the human stem cells are at rest; that is, they're not actively dividing," according to Hiroyuki Miyoshi. "There is often a problem in scaling up gene therapy procedures from mice to large animals."

"The HIV-based vector is unique in its ability to penetrate the nucleus of non-dividing cells," said Verma, adding that this ability makes the vector will allow investigators to "add genes to virtually any cell type in the body."

Genes have been successfully inserted into stem cell precursors, but only in the presence of cytokines, hormone-like substances, that can interfere with the developmental program of the stem cells. In this case, cytokines were not used to stimulate cell production. The current study represents a "major advance" in the manipulating the genetic content of blood cells, said Verma.

Before human trials can begin, safety concerns about using any kind of HIV for therapy will have to be addressed. In this study, the researchers knocked out the the pathogenic genes of the virus. The viral vectors are designed to deliver their cargo and then deactivate.

"We expect that these vectors will be safe. In fact, we have recently developed even more seriously crippled versions of the vector. It's possible that clinical trials may begin for some applications within a year," Varma added.

The study appears in the January 29,1999 issue of Science.

Related information on the Internet
Salk Institute
Gene Therapy Overview

What's News Index


Today's Health and
BioScience News
Science Update Archives Factoids Newsmaker Interviews

Custom Search on the AE Site